 NEW YORK, April 01, 2021 GLOBE NEWSWIRE -- Royalty Pharma plc Nasdaq: RPRX today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline GSK for an upfront payment of 342 million and up to 50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the U.S. and Europe. 